Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma

Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy with a median survival of 3 years despite chemoimmunotherapy. Rituximab, a chimeric anti–CD20 monoclonal antibody (mAb), has shown only modest activity as single agent in MCL. The humanized mAb milatuzumab targets CD74, an integral membra...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Alinari, Lapo, Yu, Bo, Christian, Beth A., Yan, Fengting, Shin, Jungook, Lapalombella, Rosa, Hertlein, Erin, Lustberg, Mark E., Quinion, Carl, Zhang, Xiaoli, Lozanski, Gerard, Muthusamy, Natarajan, Prætorius-Ibba, Mette, O'Connor, Owen A., Goldenberg, David M., Byrd, John C., Blum, Kristie A., Baiocchi, Robert A.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2011
Assuntos:
Lymphoid Neoplasia
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3099572/
https://ncbi.nlm.nih.gov/pubmed/21228331
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-08-303354
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares